Sequential Bevacizumab-based therapy in metastatic colorectal cancer (mCRC): results of a treatment sequencing cost analysis

被引：0
|
作者：
Rautenberg, T. [1 ]
Siebert, U. [2 ]
Arnold, D. [3 ]
Bennouna, J. [4 ]
Kubicka, S. [5 ]
Walzer, S. [1 ]
Ngoh, C. [6 ]
机构：
[1] AiM Assessment Med GmbH, Lorrach, Germany
[2] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth & Hlth Technol Assessment, Hall In Tirol, Austria
[3] Univ Hosp, Hubertus Wald Tumor Ctr, UCCH, Eppendorf, Germany
[4] Inst Cancerol Quest, Nantes, Saint Herblain, France
[5] Hannover Med Sch, D-30623 Hannover, Germany
[6] F Hoffmann La RocheLa Roche AG, Basel, Switzerland
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [21] Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
    Matsusaka, Satoshi
    Suenaga, Mitsukuni
    Mishima, Yuji
    Takagi, Koichi
    Terui, Yasuhito
    Mizunuma, Nobuyuki
    Hatake, Kiyohiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 763 - 768
  • [22] Comparative analysis of the Kohne, GERCOR and GEMCAD prognostic models in metastatic colorectal cancer (mCRC) patients treated with first-line bevacizumab-based combination chemotherapy
    Bruixola, G.
    Diaz-Beveridge, R.
    Melian, M.
    Caballero, J.
    Nino, O.
    Escoin, C.
    Akhoundova, D.
    Salvador, C.
    Segura, A.
    Gimenez, A.
    Aparicio, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S376 - S377
  • [23] An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
    Kiss, David
    Machackova, Tana
    Souckova, Kamila
    Fabian, Pavel
    Krepelkova, Iveta
    Svoboda, Marek
    Kiss, Igor
    IN VIVO, 2021, 35 (05): : 2809 - 2814
  • [24] Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
    Prager, Gerald W.
    Braemswig, Kira H.
    Martel, Alexandra
    Unseld, Matthias
    Heinze, Georg
    Brodowicz, Thomas
    Scheithauer, Werner
    Kornek, Gabriela
    Zielinski, Christoph C.
    CANCER SCIENCE, 2014, 105 (08) : 996 - 1001
  • [25] Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis
    Stein, Alexander
    Schwenke, Carsten
    Folprecht, Gunnar
    Arnold, Dirk
    CLINICAL COLORECTAL CANCER, 2016, 15 (02) : E29 - +
  • [26] Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study.
    Unseld, Matthias
    Kornek, Gabriele
    Gleiss, Andreas
    Demyantes, Svitlana
    Schwarzwald, Jost
    Bianconi, Daniela
    Andel, Johannes
    Tinchon, Christoph
    Pecherstorfer, Martin
    Eisterer, Wolfgang
    Jagdt, Bjorn
    Kretschmer, Andreas
    Gerger, Armin
    Greil, Richard
    Seebacher, Adelheid
    Krippl, Peter
    Laengle, Friedrich
    Zielinski, Christoph
    Scheithauer, Werner
    Prager, Gerald W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [27] Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An agestratified analysis.
    Vassilev, Zdravko
    Fan, Xiaozhou
    Ostojic, Helene
    Xu, Julie
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 64 - 64
  • [28] Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
    Scartozzi, M.
    Giampieri, R.
    Maccaroni, E.
    Del Prete, M.
    Faloppi, L.
    Bianconi, M.
    Galizia, E.
    Loretelli, C.
    Belvederesi, L.
    Bittoni, A.
    Cascinu, S.
    BRITISH JOURNAL OF CANCER, 2012, 106 (05) : 799 - 804
  • [29] Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy
    Demircan, Nazim Can
    Dane, Faysal
    Ozturk, Mehmet Akif
    Babacan, Nalan Akgul
    Besiroglu, Mehmet
    Kaya, Serap
    Ercelep, Ozlem
    Tanrikulu, Eda
    Halil, Suleyman
    Koca, Sinan
    Alan, Ozkan
    Hasano, Rahip
    Yumuk, Perran Fulden
    JOURNAL OF BUON, 2019, 24 (04): : 1494 - 1500
  • [30] Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
    M Scartozzi
    R Giampieri
    E Maccaroni
    M Del Prete
    L Faloppi
    M Bianconi
    E Galizia
    C Loretelli
    L Belvederesi
    A Bittoni
    S Cascinu
    British Journal of Cancer, 2012, 106 : 799 - 804
12345